Alimera Sciences, Inc. (NASDAQ:ALIM)‘s stock had its “buy” rating restated by research analysts at Cowen and Company in a research report issued on Thursday, November 2nd.
The analysts wrote, “Adaptimmune reported Q3 financials including net loss of $1MM and a cash balance.””
ALIM has been the subject of several other reports. HC Wainwright set a $5.00 target price on shares of Alimera Sciences and gave the company a “buy” rating in a research report on Tuesday, July 11th. Zacks Investment Research lowered shares of Alimera Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 13th. Finally, ValuEngine upgraded shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $3.38.
Shares of Alimera Sciences (NASDAQ:ALIM) traded down $0.02 during trading on Thursday, reaching $1.24. 170,572 shares of the company’s stock traded hands, compared to its average volume of 383,536. Alimera Sciences has a twelve month low of $1.04 and a twelve month high of $1.72. The company has a debt-to-equity ratio of -0.71, a current ratio of 4.84 and a quick ratio of 4.65.
COPYRIGHT VIOLATION WARNING: This piece was first posted by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/alimera-sciences-inc-alim-earns-buy-rating-from-cowen-and-company/1751327.html.
Several institutional investors and hedge funds have recently made changes to their positions in the company. PNC Financial Services Group Inc. lifted its holdings in shares of Alimera Sciences by 24.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock worth $251,000 after acquiring an additional 35,200 shares during the last quarter. KCG Holdings Inc. raised its holdings in Alimera Sciences by 127.0% during the 1st quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares during the last quarter. JW Asset Management LLC raised its holdings in Alimera Sciences by 15.6% during the 2nd quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its holdings in Alimera Sciences by 158.2% during the 3rd quarter. Stonepine Capital Management LLC now owns 477,226 shares of the biopharmaceutical company’s stock valued at $644,000 after buying an additional 292,399 shares during the last quarter. Hedge funds and other institutional investors own 37.33% of the company’s stock.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with our FREE daily email newsletter.